AMGN logo

Amgen Inc.

AMGN
Healthcare|Drug Manufacturers - General|US
$460.42
+0.14 (+0.03%)
DCF Value
$902.10
Graham Number
$101.79
Cash / Share
$24.38

Analyst Consensus

Buy41 analysts
Strong Buy
0
Buy
21
Hold
17
Sell
3
Strong Sell
0
Consensus Target
$415.58
Implied Upside
-9.7%
Low Target
$230.00
High Target
$500.00

Price Target Trend

Last Month
$430.55
11 targets · -6% vs price
Last Quarter
$422.40
25 targets · -8% vs price
Last Year
$384.46
65 targets · -16% vs price
All Time
$337.08
124 targets · -27% vs price

Rating Trend

Dec 25
14 buy · 15 hold · 3 sell
Jan 26
15 buy · 15 hold · 3 sell
Feb 26
14 buy · 17 hold · 3 sell
Mar 26
13 buy · 18 hold · 3 sell
Apr 26
13 buy · 19 hold · 3 sell
May 26
14 buy · 19 hold · 3 sell
Jun 26
14 buy · 18 hold · 3 sell
Jul 26
14 buy · 17 hold · 3 sell
Aug 26
15 buy · 17 hold · 4 sell
Sep 26
14 buy · 18 hold · 5 sell
Oct 26
12 buy · 17 hold · 5 sell
Nov 26
12 buy · 18 hold · 5 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Nov 4, 2026Cantor FitzgeraldCarter Gould$465.00(-2%)$473.82StreetInsider
Nov 4, 2026BernsteinCourtney Breen$400.00(-15%)$473.04StreetInsider
Nov 4, 2026RBC CapitalLuca Issi$470.00(-1%)$472.82StreetInsider
Nov 4, 2026Truist FinancialGreg Renza$398.00(-15%)$469.85StreetInsider
Nov 4, 2026Canaccord GenuityGary Nachman$440.00(-5%)$461.26StreetInsider
Nov 4, 2026Wells FargoMohit Bansal$460.00(-0%)$461.26StreetInsider
Oct 23, 2026Oppenheimer$480.00(+7%)$447.28StreetInsider
Oct 21, 2026Barclays$400.00(-9%)$438.94TheFly
Oct 13, 2026GuggenheimVamil Divan$378.00(-9%)$417.57TheFly
Oct 12, 2026BMO Capital$415.00(-0%)$415.80TheFly
Oct 12, 2026Wells Fargo$430.00(+4%)$414.87TheFly
Oct 8, 2026RBC Capital$430.00(+6%)$407.57TheFly
Oct 8, 2026Cantor FitzgeraldCarter Gould$440.00(+7%)$413.08StreetInsider
Oct 7, 2026Truist Financial$380.00(-8%)$413.67TheFly
Sep 28, 2026ScotiabankLouise Chen$500.00(+20%)$417.71TheFly
Sep 23, 2026JefferiesAkash Tewari$410.00(-0%)$410.24StreetInsider
Sep 17, 2026UBSMichael Yee$430.00(+14%)$378.42StreetInsider
Sep 4, 2026Wells FargoMohit Bansal$435.00(-2%)$444.12StreetInsider
Aug 20, 2026Piper SandlerDavid Amsellem$457.00(+3%)$442.36TheFly
Aug 19, 2026Morgan Stanley$362.00(-18%)$440.28TheFly

Recent Rating Actions

FirmActionRatingDate
Freedom BrokerdowngradeBuy →HoldNov 6, 2026
GuggenheimmaintainNeutralNov 5, 2026
Leerink PartnersmaintainMarket PerformNov 5, 2026
UBSmaintainBuyNov 4, 2026
Goldman SachsmaintainBuyNov 4, 2026
TD CowenmaintainBuyNov 4, 2026
JP MorganmaintainNeutralNov 4, 2026
CitigroupmaintainNeutralNov 4, 2026
Canaccord GenuitymaintainHoldNov 4, 2026
ScotiabankmaintainSector OutperformNov 4, 2026
BernsteinmaintainMarket PerformNov 4, 2026
Cantor FitzgeraldmaintainNeutralNov 4, 2026
Wells FargomaintainEqual WeightNov 4, 2026
Truist SecuritiesmaintainHoldNov 4, 2026
RBC CapitalmaintainOutperformNov 4, 2026
Morgan StanleymaintainEqual WeightNov 4, 2026
OppenheimermaintainOutperformOct 23, 2026
BarclaysmaintainEqual WeightOct 21, 2026
GuggenheimmaintainNeutralOct 13, 2026
BMO CapitalmaintainMarket PerformOct 12, 2026
Wells FargomaintainEqual WeightOct 12, 2026
UBSmaintainBuyOct 9, 2026
RBC CapitalmaintainOutperformOct 8, 2026
Cantor FitzgeraldmaintainNeutralOct 8, 2026
Morgan StanleymaintainEqual WeightOct 7, 2026

Earnings History

Next report: Feb 2, 2027 · EPS est. $5.65
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Nov 3, 2026$6.45$5.79$10.37B$10.07B
Aug 4, 2026$6.29$5.62$10.05B$9.43B
Apr 30, 2026$5.15$4.77$8.62B$8.58B
Feb 3, 2026$5.29$4.73$9.87B$9.47B
Nov 4, 2025$5.64$5.02$9.56B$8.97B
Aug 5, 2025$6.02$5.28$9.17B$8.94B
May 1, 2025$4.90$4.27$8.15B$8.06B
Feb 4, 2025$5.31$5.04$9.09B$8.88B

News

The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation

These are among the best the industry has to offer.

Nov 8, 2026fool.com
Amgen's Dividend Has Grown 800% Since 2011. Here's What It Pays Today

Amgen has raised its payout every year since 2011, yet the pace of those raises is cooling just as patent cliffs and drug price controls close in. One number shows whether the next raise, due soon, will hold up.

Nov 8, 2026247wallst.com
1,809 Amgen Inc. $AMGN Shares Acquired by Alta Advisers Ltd

Alta Advisers Ltd lifted its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 85.7% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,919 shares of the medical research company's stock after acquiring an additional 1,809 shares during the

Nov 6, 2026defenseworld.net
Boston Trust Walden Corp Sells 15,695 Shares of Amgen Inc. $AMGN

Boston Trust Walden Corp trimmed its holdings in Amgen Inc. (NASDAQ: AMGN) by 18.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,134 shares of the medical research company's stock after selling 15,695 shares during the period.

Nov 6, 2026defenseworld.net
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?

Amgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases. Pfizer maintains a massive global reach and offers a more conservative balance sheet with a lower valuation profile.

Nov 5, 2026fool.com
REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY

Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe  Study Examined More Than Half a Million Adults Living with Heart Disease Results Provide Important New Clinical Evidence to Inform Non-Statin Treatment Decisions for Patients  THOUSAND OAKS, Calif., Nov. 5, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfa…

Nov 5, 2026prnewswire.com
Amgen Inc. $AMGN Shares Sold by AIA Group Ltd

AIA Group Ltd cut its holdings in Amgen Inc. (NASDAQ: AMGN) by 25.8% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 15,607 shares of the medical research company's stock after selling 5,422 shares during the period. AIA Group Ltd's holdings in Amgen were worth

Nov 5, 2026defenseworld.net
2,369 Shares of Amgen Inc. $AMGN Bought by First Nebraska Trust Co

First Nebraska Trust Co acquired a new stake in shares of Amgen Inc. (NASDAQ: AMGN) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,369 shares of the medical research company's stock, valued at approximately $999,000. Other institutional

Nov 5, 2026defenseworld.net
Blue Chips Surge Past 2.8% as VIX Drops Below 18 While Oil Sinks Nearly 8%

/PRNewswire/ -- Stock Preachers News Commentary - Wall Street roared higher this week, with the Dow jumping 2.87% in a single session to a record 53,275.11 and

Nov 4, 2026prnewswire.com
Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data

Amgen Inc. (NASDAQ:AMGN) shares are trading close to its 52-week high on Wednesday after the company reported better-than-expected third-quarter financial results and raised its fiscal 2026 guidance.

Nov 4, 2026benzinga.com
AMGN Q3 Earnings Call Highlights Pipeline and Raised Outlook

Amgen raises its 2026 outlook after Q3 earnings and revenue beat estimates, as IMDELLTRA advances and MariTide offers potential long-term growth opportunities.

Nov 4, 2026zacks.com
AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance

Amgen shares fall despite Q3 earnings and revenue beats. Steep declines in Prolia and Xgeva offset strong growth across key drug portfolios and raised 2026 guidance.

Nov 4, 2026zacks.com
Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript

Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript

Nov 3, 2026seekingalpha.com
What Amgen (AMGN) Said on Its Q3 Earnings Call

Amgen NASDAQ: AMGN reported third-quarter revenue growth of 8% year over year to $10.4 billion, supported by broad-based demand across its portfolio and continued clinical progress in several late-stage programs. The company raised its full-year revenue and adjusted earnings outlook while highlighting growth in cardiovascular, bone health, inflammation, rare disease, oncology and biosimilar medicines.

Nov 3, 2026marketbeat.com
Amgen (AMGN) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Nov 3, 2026zacks.com
Amgen (AMGN) Tops Q3 Earnings and Revenue Estimates

Amgen (AMGN) came out with quarterly earnings of $6.45 per share, beating the Zacks Consensus Estimate of $5.74 per share. This compares to earnings of $5.64 per share a year ago.

Nov 3, 2026zacks.com
AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

THOUSAND OAKS, Calif., Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026.

Nov 3, 2026prnewswire.com
Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?

AMGN, PFE, MRNA, NVO and VTRS are set to report this week as recent beats and key drug demand set up a pivotal Q3 earnings test for pharma giants.

Nov 2, 2026zacks.com
Amgen Just Gave Its Shareholders Great News

Amgen's cancer drug Imdelltra has been shown to be effective in treating advanced lung cancer when paired with AstraZeneca's Imfinzi. The risk of death was cut by 58% for patients who used the combination treatment.

Nov 2, 2026fool.com
How to Build $6,800 a Month in Dividend Income Without Selling a Single Share

Collecting four figures a month from dividends without ever selling a share sounds straightforward until you price out what it actually costs and see which companies are holding the whole structure together.

Oct 30, 2026247wallst.com